Kaili Ren
Research Subjects
Kaili Ren has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Colin Anderson-Smits
Global Evidence and Outcomes, Data and Quantitative Sciences Institute, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA
2 shared publications- Csaba Siffel
Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA; College of Allied Health Sciences, Augusta University, Augusta, Georgia, USA
2 shared publications - Drishti Shah
IQVIA, Falls Church, Virginia
2 shared publications - Joshua Richter
Icahn School of Medicine at Mount Sinai, New York, USA
2 shared publications - Marta Kamieniak
Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA
2 shared publications - Jasjit K. Multani
IQVIA
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Multiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns
Patients with multiple myeloma (MM) and secondary immunodeficiency (SID) are at risk of infection‐related morbidity and mortality owing to the disease process and treatment toxicity. This retrospective cohort study used anonymized data from the Optum‐Humedica database (October 2015–March 2020) to assess the burden of infection in patients with MM and SID versus patients without SID. Patients aged ≥ 18 years with confirmed MM were assigned to SID and no‐SID cohorts using an algorithm considering serum IgG levels < 5.0 g/L, hypogammaglobulinemia diagnosis codes, and ≥ 1 major infection. Patients with SID were stratified into those treated or not treated with immunoglobulin replacement therapy (IgRT and no‐IgRT cohorts). At 12 months follow‐up, a greater proportion of the SID cohort than the no‐SID cohort experienced infections (58.9% vs. 31.3%; p < 0.001), severe infections (29.8% vs. 10.6%, p < 0.001), and infection‐related hospitalizations (26.9% vs. 9.1%; p < 0.001). Bacterial infections were the most common infection type (SID cohort, 49.2%; no‐SID cohort, 26.1%; IgRT cohort, 70.4%; no‐IgRT cohort, 45.1%). Use of anti‐infectives and healthcare resource utilization was higher in the SID cohort than in the no‐SID cohort. Median overall survival was shorter in the SID versus no‐SID cohort (12.6 vs. 14.7 months; p < 0.001) and was similar in the IgRT versus no‐IgRT cohort (8.5 vs. 12.5 months; p = 0.446). Among patients with MM and SID, the higher infection burden in patients treated with IgRT than no‐IgRT suggests the IgRT cohort was a more vulnerable population. A better understanding of SID burden may improve outcomes for patients with MM.
- 1 January 2025
- Published by Wiley in Advances in Hematology
- Vol. 2025 (1)
Open AccessMultiple Myeloma and Secondary Immunodeficiency: A Retrospective Database Analysis Assessing Burden of Infection and Treatment Patterns
Patients with multiple myeloma (MM) and secondary immunodeficiency (SID) are at risk of infection‐related morbidity and mortality owing to the disease process and treatment toxicity. This retrospective cohort study used anonymized data from the Optum‐Humedica database (October 2015–March 2020) to assess the burden of infection in patients with MM and SID versus patients without SID. Patients aged ≥ 18 years with confirmed MM were assigned to SID and no‐SID cohorts using an algorithm considering serum IgG levels < 5.0 g/L, hypogammaglobulinemia diagnosis codes, and ≥ 1 major infection. Patients with SID were stratified into those treated or not treated with immunoglobulin replacement therapy (IgRT and no‐IgRT cohorts). At 12 months follow‐up, a greater proportion of the SID cohort than the no‐SID cohort experienced infections (58.9% vs. 31.3%; p < 0.001), severe infections (29.8% vs. 10.6%, p < 0.001), and infection‐related hospitalizations (26.9% vs. 9.1%; p < 0.001). Bacterial infections were the most common infection type (SID cohort, 49.2%; no‐SID cohort, 26.1%; IgRT cohort, 70.4%; no‐IgRT cohort, 45.1%). Use of anti‐infectives and healthcare resource utilization was higher in the SID cohort than in the no‐SID cohort. Median overall survival was shorter in the SID versus no‐SID cohort (12.6 vs. 14.7 months; p < 0.001) and was similar in the IgRT versus no‐IgRT cohort (8.5 vs. 12.5 months; p = 0.446). Among patients with MM and SID, the higher infection burden in patients treated with IgRT than no‐IgRT suggests the IgRT cohort was a more vulnerable population. A better understanding of SID burden may improve outcomes for patients with MM.
- Open Access
- 10 April 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (8) , 553-563
Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy
- 10 April 2024
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24 (8) , 553-563
Open AccessBurden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy